Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | ESRRA | P11474 | 6/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.57 |
| ▸ | PGR | P06401 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.57 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | ESRRB | O95718 | 5/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841525 | 1.00 | ESR1 (0.65) | ESR1ESR2HDAC3HDAC6ESRRA | |
| SCHEMBL14569704 | 1.00 | ESR1 (0.65) | ESR1ESR2HDAC3HDAC6ESRRA | |
| SCHEMBL16485502 | 1.00 | ESR1 (0.65) | ESR1ESR2HDAC3HDAC6ESRRA | |
| SCHEMBL14569705 | 0.89 | ESR1 (0.64) | ESR1ESR2HDAC3HDAC6ESRRA | |
| SCHEMBL5353798 | 0.88 | LMNA (0.58) | ESR1ESR2HDAC3HDAC6ESRRA | |
| SCHEMBL14559142 | 0.88 | LMNA (0.58) | ESR1ESR2HDAC3HDAC6ESRRA | |
| SCHEMBL10627661 | 0.88 | ESR1 (0.63) | ESR1ESR2HDAC3HDAC6ESRRA | |
| SCHEMBL17302818 | 0.87 | ESR1 (0.70) | ESR1ESR2HDAC3HDAC6ESRRA | |
| SCHEMBL24684756 | 0.87 | ESR1 (0.69) | ESR1ESR2HDAC3HDAC6ESRRA | |
| SCHEMBL24102515 | 0.87 | ESR1 (0.69) | ESR1ESR2HDAC3HDAC6ESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209853-A1 | Orally active 7.alpha.-alkyl androgens | AKZO NOBEL N.V. (NL) | 2004-10-21 | — | — | US | disclosed |
| US-6780854-B2 | MALE CONTRACEPTION | AKZO NOBEL NV (NL) | 2004-08-24 | — | — | US | disclosed |
| US-6756366-B1 | 19-NORTESTOSTERONE DERIVATIVES; ORALLY ACTIVE; HIGH POTENCY | AKZO NOBEL N.V. (NL) | 2004-06-29 | — | — | US | disclosed |
| EP-1203011-B1 | ORALLY ACTIVE ANDROGENS | AKZO NOBEL NV (NL) | 2004-01-02 | — | — | EP | disclosed |
| EP-1212345-B1 | ORALLY ACTIVE 7-ALPHA-ALKYL ANDROGENS | AKZO NOBEL NV (NL) | 2003-08-06 | — | — | EP | disclosed |
| US-20030087886-A1 | Orally active androgens | LOOZEN HUBERT JAN JOZEF (NL) | 2003-05-08 | — | — | US | disclosed |
| US-6541465-B2 | Delta 14 derivatives of 19- nortestosterone, useful for the preparation of a medicine for treating androgen insufficiency | AKZO NOBEL N.V. (NL) | 2003-04-01 | — | — | US | disclosed |
| EP-1212345-A2 | ORALLY ACTIVE 7.ALPHA.-ALKYL ANDROGENS | Akzo Nobel N.V. (NL) | 2002-06-12 | — | — | EP | disclosed |
| EP-1203011-A1 | ORALLY ACTIVE ANDROGENS | Akzo Nobel N.V. (NL) | 2002-05-08 | — | — | EP | disclosed |
| US-20020022609-A1 | Orally active androgens | LOOZEN HUBERT JAN JOZEF (NL) | 2002-02-21 | — | — | US | disclosed |
| US-6313108-B1 | TREATING ANDROGEN INSUFFICIENCY | AKZO NOBEL N.V. (NL) | 2001-11-06 | — | — | US | disclosed |
| WO-2001005806-A1 | ORALLY ACTIVE ANDROGENS | AKZO NOBEL N.V. (NL) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000059920-A2 | ORALLY ACTIVE 7.ALPHA.-ALKYL ANDROGENS | AKZO NOBEL N.V. (NL) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087886-A1 | Orally active androgens | NR5A1, AR, CYP17A1 | ESR1 112/4885ESR2 61/4885HDAC3 127/4885 |
| US-20020022609-A1 | Orally active androgens | NR5A1, AR, CYP17A1 | ESR1 109/4885ESR2 61/4885HDAC3 120/4885 |
| US-20040209853-A1 | Orally active 7.alpha.-alkyl androgens | NR5A1, AR, SHBG | ESR1 97/4885ESR2 45/4885HDAC3 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.